Human immunodeficiency virus 1 clade B multi-antigen cytotoxic T-lymphocyte epitopes (HIV-1 CTL epitopes)

This target represents a comprehensive set of cytotoxic T-lymphocyte (CTL) epitopes derived from the major structural, enzymatic, and regulatory proteins of HIV-1 clade B, specifically Gag, Pol, Env (gp160), Rev, Nef, and Tat [1][2]. These epitopes are short peptide sequences that, when delivered via vaccine platforms such as DNA plasmids or viral vectors, are processed and presented by Major Histocompatibility Complex (MHC) class I molecules on the surface of host cells [3]. The biological functions of the source proteins are critical to the viral life cycle, including structural assembly (Gag), replication and processing (Pol), and the regulation of viral gene expression (Tat, Rev) [4]. By targeting multiple proteins simultaneously, this approach aims to elicit a broad and robust CD8+ T-cell response capable of recognizing and lysing HIV-infected cells at various stages of infection [5]. This multi-antigen strategy is specifically designed to mitigate the risk of viral escape, as the high mutation rate of HIV-1 makes single-antigen targets highly susceptible to resistance [6]. In clinical development, these epitopes are primarily utilized in therapeutic vaccines intended to achieve long-term viral suppression or a functional cure for HIV/AIDS [7].

Other names

HIV-1 polyepitopeHIV-1 clade B Gag-Pol-Env-Rev-Nef-Tat antigensHIV-1 multi-protein vaccine targetHIV-1 CTL epitope clusterHIV-1 clade B CTL epitopes

Induction of broad-based, antigen-specific CD8+ cytotoxic T-lymphocyte (CTL) responses to recognize and eliminate HIV-infected cells.